Scholars Central

Conference abstractPublished 7 Dec 2017

Soarfenib effect on human colon cancer cells HCT116 and HCT116 p53-/-

Authors: M Al Hassan, A Baltaji, J Borjac, R Fakhouri, J Usta

Beirut Arab University, Lebanon; American University of Beirut, Lebanon

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Sorafenib, a kinase inhibitor, has been approved among the drugs for the treatment of radioactive iodine resistant thyroid carcinoma, primary kidney and liver cancer. Reported targets of sorafenib include VEGFR, Raf family, and PDGFR belonging to the general class of tyrosine kinases. Blocking growth signals in kidney and breast cancers underlie one of the mechanisms of sorafenib antitumor effectsâÂ?Â? leading to cell death. We hereby examine the effect of sorafenib on human colon carcinoma cell-line HCT116. We also investigate the possible role of p53 in mediating this effect using mutant HCT116 p53-/- cells. Cultured wild and mutant cells are treated with sorafenib (0-75Ã?µM) for 24 hr. This is followed by assessing the viability of cells using MTT and trypan blue exclusion assays. We also examined if sorafenib mode of action is mediated by ROS. Levels of ROS were determined in the presence and absence of antioxidants using the colorimetric NBT assay. Our preliminary results show a concentration dependent decrease in viability (trypan blue) with an estimated EC50 of 10 and 25 Ã?µM for HCT116 and HCT116 p53-/- respectively. Compared to trypan blue, MTT results were similar in case of HCT116 p53-/- but were significantly different with HCT116. Furthermore we obtained a significant increase in level of ROS of: 37.11% and 31.30% for HCT116 and HCT116p53-/- respectively. However, 2 hr. pre-incubation of cells with antioxidants, Trolox, N-acetylcysteine (NAC), and catalase, prior to sorafenib treatment, exerted no different effect. No restoration of viability or decrease in generated ROS level was noted. Our preliminary findings show that sorafenib action is independent of ROS level and p53 expression and further investigations on the mechanism(s) of sorafenib action are ongoing.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Proteomics & Bioinformatics.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Proteomics & Bioinformatics
  • SubjectBiochemistry & Biotechnology
  • BylineArticles whose byline prints “M Al Hassan”
  • BylineArticles whose byline prints “A Baltaji”
  • BylineArticles whose byline prints “J Borjac”
  • BylineArticles whose byline prints “R Fakhouri”
  • BylineArticles whose byline prints “J Usta”